Poor outcomes include lower response rate to chemotherapy, higher mortality, recurrence
WEDNESDAY, Oct. 7, 2020 (HealthDay News) — Smoking is tied to worse bladder cancer outcomes following radical cystectomy, according to a review published online Oct. 1 in The Journal of Urology.
Giovanni E. Cacciamani, M.D., from the University of Southern California in Los Angeles, and colleagues conducted a systematic literature search to identify studies evaluating tobacco smoking exposure, duration, intensity, and cessation on response to neoadjuvant chemotherapy and long-term survival outcomes in patients undergoing radical cystectomy for bladder cancer.
Based on 17 studies (13,777 patients), a pooled meta-analysis revealed that active smokers had an increased risk for overall mortality (hazard ratio [HR], 1.21), cancer-specific mortality (HR, 1.24), and bladder cancer recurrence (HR, 1.24). When analyzing only patients who underwent neoadjuvant chemotherapy followed by radical cystectomy, nonsmokers and never smokers showed an advantage in terms of neoadjuvant chemotherapy complete response rate compared with active smokers (HR, 0.47).
“Appropriate preoperative counseling, together with tightened follow-up, may have a pivotal role in improving the smoking-related long-term survival outcomes in patients with bladder cancer,” the authors write.
Chemo-Free Combo of Four Targeted Therapies Shows Promise in Metastatic Breast Cancer
Preoperative Chemo + Immunotherapy Combo Shrinks Head, Neck Cancer Tumors
Heat-Not-Burn Tobacco, E-Cigarettes May Be Linked to Postoperative Recurrence of Crohn Disease
Dexrazoxane Offers Lasting Doxorubicin Cardioprotective Effect in Childhood Cancer Survivors
December 2024 to 2025 Saw Significant Increase in Leucovorin Dispensing
Long-Term Medication Adherence Tied to Lower Cardiovascular Event Rate in Type 2 Diabetes
Once-Weekly Oral Islatravir-Lenacapavir Noninferior to Daily B/F/TAF in HIV
28 Percent of U.S. Adults With HTN Eligible for Treatment Under New Guidelines